Ironwood Pharmaceuticals
IRWD
124 hedge funds and large institutions have $1.32B invested in Ironwood Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 46 increasing their positions, 39 reducing their positions, and 13 closing their positions.
80% more call options, than puts
Call options by funds: $6.05M | Put options by funds: $3.37M
18% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 39
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
1% more capital invested
Capital invested by funds: $1.32B → $1.32B (+$7.57M)
0% more funds holding
Funds holding: 124 → 124 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$18M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$14.2M |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$10.4M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$9.25M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$3.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$12.4M |
| 2 |
Millennium Management
New York
|
-$9.22M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.11M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$7.27M |
| 5 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
-$4.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GACM
126
Green Arrow Capital Management
New York
| – | -$1.78M | -179,100 | Closed |
|
|
HLA
127
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$727K | -73,345 | Closed |
|
|
HCM
128
Harvey Capital Management
Palm Beach,
Florida
| – | -$673K | -67,939 | Closed |
|
129
Nomura Asset Management
Tokyo,
Japan
| – | -$474K | -47,760 | Closed |
|
|
ST
130
Spot Trading
Chicago,
Illinois
| – | -$399K | -44,481 | Closed |
|
|
PP
131
PDT Partners
New York
| – | -$406K | -40,942 | Closed |
|
|
SCA
132
SAC Capital Advisors
Stamford,
Connecticut
| – | -$290K | -29,240 | Closed |
|
|
OTPPB
133
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
| – | -$273K | -27,534 | Closed |
|
134
SG Americas Securities
New York
| – | -$209K | -21,066 | Closed |
|
135
Arrowstreet Capital
Boston,
Massachusetts
| – | -$180K | -18,096 | Closed |
|
|
HCM
136
Highbridge Capital Management
New York
| – | -$150K | -15,133 | Closed |
|
|
RFC
137
Russell Frank Company
Seattle,
Washington
| – | -$6K | -592 | Closed |
|
IRWD Hedge Fund Activity: Q4 2013 in Review
124 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2013, worth a combined $1.32B — up 0.58% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new IRWD positions and 13 closed out — a net gain of 2 holders — while 46 added to existing stakes and 39 trimmed.
The largest buyer was BVF Inc, adding an estimated $18M. The largest seller was Morgan Stanley, cutting an estimated $12.4M.
- 124 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $1.32B of Ironwood Pharmaceuticals stock for Q4 2013, up 0.58% quarter-over-quarter.
- 15 funds opened new Ironwood Pharmaceuticals positions in Q4 2013 and 13 closed out, a net change of +2 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2013 was BVF Inc, an estimated $18M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2013 was Morgan Stanley, an estimated $12.4M sold.
Based on aggregated 13F filings for Q4 2013.